Defeat Duchenne Canada launches 2023 Research Grant Program
Defeat Duchenne Canada (DDC) is the country’s largest charitable source of investment in cutting-edge Duchenne muscular dystrophy research. DDC have funded $16 million into the most promising international research focussed on improving outcomes for all individuals with this progressive disease.
DDC invites all investigators working on translational or clinical Duchenne research to apply to their 2023 Research Grant Program!
Funding Criteria
Read the full funding criteria to learn more about the grant program.
Upcoming Deadlines
The deadline to submit a letter of intent is April 21st, 2023.
Submit a letter of intent through the DDC web portal.
Read next...
Hope on the Horizon: Trials, Treatments and Therapies for DMD, DM1 & MG
Nov 25-28, 2025 | Join us at Hope on the Horizon to learn more about the treatment and clinical trial landscape for Duchenne Muscular Dystrophy, Myotonic Dystrophy Type 1 and Myasthenia Gravis from key experts in the field!
2026 Awards Now Open for Nominations!
We’re proud to recognize outstanding achievements across the neuromuscular research community with our Three awards: Publication of the Year, Early Career Biomedical/Clinical Researchers of the Year.
A Milestone in Neuromuscular Care: AGAMREE® (vamorolone) Approved as the First Treatment for Duchenne Muscular Dystrophy in Canada
Health Canada has approved AGAMREE® (vamorolone), the first-ever treatment for Duchenne Muscular Dystrophy (DMD) in Canada. Patient Support Program opens for enrollment on October 10, 2025.